Blood cell precursors
In vivo lineage marking
A B S T R A C T
One of the principal issues facing biomedical research is to elucidate developmental pathways and to establish the fate of stem and progenitor cells in vivo. Hematopoiesis, the process of blood cell formation, provides a powerful experimental system for investigating this process. Here, we employ transcriptional regulatory elements from the stem cell leukemia (SCL) gene to selectively label primitive and definitive hematopoiesis. We report that SCLlabelled cells arising in the mid to late streak embryo give rise to primitive red blood cells but fail to contribute to the vascular system of the developing embryo. Restricting SCLmarking to different stages of foetal development, we identify a second population of multilineage progenitors, proficient in contributing to adult erythroid, myeloid and lymphoid cells. The distinct lineage-restricted potential of SCL-labelled early progenitors demonstrates that primitive erythroid cell fate specification is initiated during mid gastrulation.
Our data also suggest that the transition from a hemangioblastic precursors with endothelial and blood forming potential to a committed hematopoietic progenitor must have occurred prior to SCL-marking of definitive multilineage blood precursors. 1.
Introduction
Hematopoiesis, the process of blood cell formation, provides a powerful system for studying lineage specification and cellular commitment. Although the ontogeny of blood cells has been extensively investigated, the initial emergence of blood cell progenitors and hematopoietic stem cells (HSCs) is still controversial (Cumano and Godin, 2007; Lux et al., 2008; Rhodes et al., 2008) . It is also not well understood when vascular and hematopoietic lineages diverge during ontogeny and when hematopoietic specification is first established (Flamme et al., 1997; Haar and Ackerman, 1971; Huber et al., 2004; Kinder et al., 1999; Lugus et al., 2005; Ueno and Weissman, 2006) . In mice, evidence for hematopoietic activity occurs around day 7.2 (E7.2) of gestation, which is characterized by primitive erythroid progenitors (Ery P ) that will give rise to large, nucleated erythrocytes (Palis, 2008) . This first wave of primitive blood cell formation is followed by the emergence of definitive hematopoietic progenitors, proficient to generate the complete repertoire of adult blood (Godin and Cumano, 2002; Mikkola and Orkin, 2006) .
Several lines of evidence suggest that the basic helixloop-helix transcription factor SCL (also known as TAL1 or TCL5) is a key regulator for primitive and definitive hematopoiesis (Begley and Green, 1999; Lecuyer and Hoang, 2004) . Genetic studies indicated that SCL function is required for the specification of primitive erythroblasts deriving from a mesodermal precursor (Ery P ) at the origin of blood and endothelium (D'Souza et al., 2005; Shivdasani et al., 1995) . In addition, SCL is necessary for the establishment of definitive HSCs in the embryo proper (Dooley et al., 2005; Patterson et al., 2005; Porcher et al., 1996; Robb et al., 1995) . Though these studies indicated a functional requirement for SCL in hematopoietic development, they did not elucidate the origin of primitive and definitive SCL + blood progenitors. The use of SCL-reporter mice is also not appropriate for correlating marker gene expression and lineage fate because SCL activity is down-regulated within some cells of the hematopoietic system and maintained in others (Delabesse et al., 2005; Elefanty et al., 1999; Gottgens et al., 2000 Gottgens et al., , 2004 Sanchez et al., 1999 Sanchez et al., , 2001 Sinclair et al., 1999) . To be able to trace the origin of primitive and definitive hematopoietic cells and to establish the progenitor-progeny relationship between SCL + HSCs and more differentiated blood cells, it is necessary to use a lineage-tracking system in which cells that express SCL, or are the progeny of SCL-expressing cells, will be permanently marked.
Here, we have used the previously established SCL-tTA-2S knock-in mouse model (Bockamp et al., 2006) for conditional in vivo tagging and lineage tracing. We report that the first SCL-labelled cells arise in the mid to late streak embryo and find that these progenitors give rise to primitive erythropoiesis. Restricting in vivo marking to different stages of foetal development revealed a second population of progenitors, which have the potential to contribute to adult blood. Most strikingly, permanent SCL-labelling failed to mark endothelial cells of the developing conceptus. Our findings provide a developmental map for the initial specification of hematopoiesis in the mouse foetus.
Results
2.1. SCL-tagged cells first emerge in the extra-embryonic mesoderm and are subsequently localized to the yolk sac and the developing vasculature
To mark putative hematopoietic progenitors in vivo, we generated triple transgenic mice containing the SCL-tTA-2S transgene (Bockamp et al., 2006) together with an inducible Cre-recombinase (Saam and Gordon, 1999) and the ROSA26 flox-STOP-flox lacZ Cre-reporter gene (R26R lacZ (Soriano, 1999) ) that allows visualizing recombined cells and their progeny (Fig. 1) . In accordance with the described onset of SCL activity, tTA-2S mRNA expression was present in E7.2 SCLtTA-2S embryos (data not shown). Furthermore, analysis of triple transgenic foetuses between E7 and E7.75 demonstrated the emergence of b-galactosidase + (b-gal + ) cells at embryonic day E7.2 (S1). In these mid to late streak foetuses, SCL-tagged b-gal + cells were localized to the extra-embryonic mesoderm ( Fig. 2A) . As development proceeded to the neural plate and headfold stage, SCL-tagged cells were confined to the mesoderm of the visceral yolk sac (Fig. 2B) . Interestingly, SCL-tagging did not target intra-embryonic sites in presomitic and early somitic embryos (<5 somites). As shown in Fig. 2C , in 5-7 somite embryos b-gal + cells started to emerge in the dorsal aorta of the embryo proper and localized to the yolk sac blood islands and the allantois. At embryonic day E9.5 intense lacZ staining highlighted the small and large vitelline vessels of the yolk sac (S2) and the vascular network of the embryo proper (Fig. 2D ). These findings suggested that SCL-tagging targets early hematopoietic and/or vascular development.
2.2. SCL-tagging targets primitive erythropoiesis but does not contribute to the newly formed vasculature of the conceptus Primitive erythroblasts are the first hematopoietic cell type to form during mammalian embryogenesis. To investigate whether SCL-tagged cells contributed to primitive erythropoiesis, we used the RAGE flox-STOP-flox EGFP mouse line (RAGE EGFP (Constien et al., 2001) ) as a Cre-reporter for SCL-marked cells. Analogous to our previous findings (Fig. 2) , in this mouse model SCL-tagged EGFP + cells were completely confined to the extra-embryonic mesoderm of early somite foetuses (S3 and S4). As shown in Fig. 3A , flow cytometric analysis of E8.5 dissected extra-embryonic yolk sacs indicated that about one third of the analyzed cells expressed EGFP together with the Ter119 pre-foetal liver erythroid-specific marker. The expression of Ter119 on SCL-marked cells therefore demonstrated that these cells were primitive erythrocytes.
To further determine the relative percentages of distinct primitive red blood cell subtypes prior to the appearance of the first definitive erythroblasts, EGFP À and SCL-tagged EGFP + cells from whole E9 conceptuses were analyzed by flow cytometry. As shown in Fig. 3B , only about 0.18% of all viable cells were EGFP-tagged. Based on their expression for CD71 and Ter119 five subpopulations could be established (quadrants I to V in Fig. 3B ). Compared to the EGFP À fraction, E9 EGFP + cells were much less abundant in the progenitor and early proerythroblasts population (Fig. 3B , upper plot, quadrant I). Since CD71 is not exclusively expressed on erythrocytes but also on highly proliferating cells (Trowbridge and Omary, 1981 ) the reduced percentage of CD71 + /Ter119 À EGFP-expressing cells in quadrant I most likely reflects selective SCL-marking of early proerythroblasts and the lack of marking of non-hematopoietic cells. However, SCL-tagged proerythroblasts, early and late basophilic erythroblasts, chromatophilic and orthochromatophilic erythroblasts were present in the E9 conceptus ( Fig. 3B , upper plot, quadrants II, III and IV). By contrast, only very few EGFP-expressing cells were detected in the late orthochromatophilic erythroblast and reticulocytes fraction (quadrant V), the most part of which contains enucleated cells that have lost their ability to express the EGFP reporter gene. Our analysis thus revealed that EGFP-tagged cells expressed CD71 and Ter119 in a manner which recapitulated the stepwise developmental maturation pattern for primitive erythroblasts (Fraser et al., 2007) . Next, we wanted to clarify whether SCL-tagged cells also contribute to the three-dimensional network of tubules that constitutes the primary vascular plexus, which later undergoes reorganization, sprouting and remodelling to form the vitelline vessels. Given the shared expression of known endothelial markers on both primitive blood and blood vessel cells Redmond et al., 2008) it is not possible to unambiguously discriminate between these two lineages by flow cytometry. To circumvent this problem, SCL-induced lacZ reporter gene activation was analyzed by confocal microscopy. Ex Ec, extra-embryonic ectoderm; PrC, proamniotic cavity; AC, amniotic cavity; Exo C, exocoelomic cavity; Pro; prosencephalon; Mes, mesencephalon; Met, metencephalon; He/LB, heart and liver bulge; ISA, intersomitic artery; S, somites.
Strikingly, in E9 SCL-marked embryos, no co-localization of SCL-tagged cells (depicted in blue) with the endothelial cellcontaining tubes of the yolk sac capillary network (in green) was detected ( Fig. 4A-F ). In line with the previously observed tagging of primitive erythrocytes, we found expression of bgal in large round cells. Equally, the microscopic analysis of intra-embryonic structures revealed no contribution of SCLmarked cells to the endothelial networks of the E9 embryo proper. Fig. 4G -L shows representative images of this analysis. Again the presence of large round b-gal + cells within b-gal À vessels was apparent. Furthermore, no co-staining of SCL-tagged cells with endothelial structures was found in E10.5 and E12.5 embryos (S5 and data not shown). Taken together these results demonstrate that the SCL-based system did not target endothelial structures of the developing embryo till E12.5.
SCL-labelling targets progenitors for adult blood
With the tTA-2S mouse model it is possible to conditionally deactivate cell marking at any given time ((Bockamp et al., 2006; Wilson et al., 2008) and Fig. 1 ). To determine the time required for shutting down SCL-marking in the developing embryo, pregnant mothers were exposed to doxycycline (DOX) for different time periods before the initial appearance of SCL-labelled b-gal + cells. Pregnant mothers receiving DOX for 42 h prior to the onset of SCL-mediated lacZ reporter gene activation failed to give rise to SCL-marked foetuses (S6). This finding indicated that DOX application for 42 h is sufficient for completely extinguishing SCL-mediated cell tagging in the developing foetus. This kinetic not only takes into account the time DOX needs to pass the placenta and to prevent irreversible Cre-recombination, but also accommodates for the known asynchronous embryonic development during gestation (Downs and Davies, 1993) . In order to determine the ability of SCL-marked progenitors to contribute to adult blood, SCL-tagging was deactivated at separate time points during embryogenesis and the fate of labelled progenitors was traced into adulthood. As shown in Fig. 5 and S7, in triple transgenic adult animals permanently exposed to DOX (+DOX), we detected no SCL-marked cells. By contrast, we found up to 10% of EGFP + cells in triple transgenic mice, which never received DOX (ÀDOX). Therefore, cell marking was completely dependent on DOX with no illegitimate reporter gene activation taking place. When tagging was allowed until E7.75 (application of DOX at E6), SCL-marked cells failed to contribute to adult hematopoiesis ( Fig. 5 and S7 ). By contrast, when SCL-labelling was allowed until E8.75 (DOX E7.0), a small proportion of EGFP + cells appeared in the bone marrow and the spleen of adult mice ( Fig. 5 and S7 ). Marking levels further increased when labelling was extended until E9 and E9.25 (DOX application at E7.25 and E.7.5). These findings indicated that conditional SCL-mediated in vivo tagging targeted two independent populations, namely Ery P s, giving rise to primitive erythroid development and definitive progenitors which contribute to adult blood.
SCL-tagged progenitors have multilineage potential
The long-term function of HSCs that permits them to support hematopoiesis throughout life is thought to depend on definitive hematopoietic progenitors which arise during embryonic development (Godin et al., 1995; Gothert et al., 2005; Medvinsky and Dzierzak, 1996; Rhodes et al., 2008; Samokhvalov et al., 2007) . Our above results indicated that cells genetically tagged between E8.75 and E9.25 were proficient to contribute to adult hematopoietic tissues. To test whether these cells were able to give rise to all mature hematopoietic lineages, potentially EGFP-expressing cells were isolated from five month old mice and analyzed by flow cytometry. As expected, no EGFP + cells were present in triple transgenic animals continuously exposed to DOX (Fig. 6A) (Fig. 6B) . Therefore, perma- previous analysis, no lineage contribution was detected when SCL-tagging was stopped at E7.75 (Fig. 6C) . To assay the lineage potential of reporter-labelled cells marked between E8.75 and E9.25, cells from this cohort were also subjected to lineage analysis. As shown in Fig. 6D-F Our findings thus indicate that SCL-tagging targets a population of definitive hematopoietic progenitors in the developing mouse embryo, proficient to contribute to adult erythroid, myeloid and lymphoid development. We conclude that SCLtagging targets progenitors that support adult hematopoiesis and that these progenitors can be detected at E8.75, when the transition from the early somite stage to functional foetal circulation is initiated.
Discussion
The goal of the present paper was to investigate the origin of primitive and definitive hematopoiesis during embryonic ontogeny. Using lineage marking we demonstrate primitive erythroid lineage specification in vivo. Furthermore, time-restricted labelling revealed a population of definitive blood cell progenitors capable of contributing to adult hematopoiesis.
In the past a number of studies have investigated the origin of primitive hematopoiesis in the early mouse conceptus Furuta et al., 2006; Huber et al., 2004; Kinder et al., 1999; Lancrin et al., 2009; Ueno and Weissman, 2006) . While these studies provided direct proof for the existence of a common hemangioblastic progenitor for blood and endo- thelial cells and for the subsequent specification of blood and endothelial lineages, it is still unclear when primitive blood cell development is first initiated. Our mouse model now extends these studies and uses in vivo tagging to trace the developmental origin of hematopoiesis. This approach has distinct advantages over prior experimental strategies since it avoids the removal of cells from their native developmental niches and also provides the opportunity to stop marking at any given time. Congruent with the expected origin of foetal hematopoiesis, we found the first SCL-tagged cells in the extra-embryonic mesoderm of mid to late streak gastrulating embryos ( Fig. 2A) . Subsequently, marked cells assembled in the yolk sac blood islands and finally localized to the vascular network of the developing embryo and the vitelline vessels of the yolk sac (Fig. 2B-D and S2 ). Flow cytometry and confocal microscopy verified that SCL-tagging targeted primitive erythropoiesis but failed to mark the newly forming vascular network of the yolk sac and the embryo proper (Figs. 3 and 4 and S5). The observed lack of endothelial contribution demonstrates that initial SCL-marking must have started downstream of a common precursor with endothelial and hematopoietic potential and strongly supports the previously proposed concept that primitive hematopoietic and endothelial lineage commitment diverges prior to the establishment of the visceral yolk sac (Kinder et al., 1999; Ueno and Weissman, 2006) . Importantly, in the present paper we demonstrate for the first time the emergence of genetically labelled progenitors, proficient in giving rise to primitive erythrocytes in vivo. Our findings thus position these progenitors at the origin of primitive embryonic hematopoiesis. In addition to primitive blood cell development, SCL-tagging targeted a second population of cells, capable of contributing to adult blood. The sites of origin and the initial appearance of definitive hematopoietic progenitors has been a longstanding and controversial issue of intense investigation. Now there is evidence that progenitors with definitive hematopoietic potential do not arise from a single embryonic origin but instead are autonomously generated in different sites which include the yolk sac, the paraaortic splanchnopleura/AGM-region and the placenta (Godin et al., 1995; Medvinsky and Dzierzak, 1996; Rhodes et al., 2008; Samokhvalov et al., 2007; Zovein et al., 2008) . These studies also suggested that the spatio-temporal appearance of definitive hematopoietic progenitors takes place in two consecutive waves, namely in the yolk sac of the E7.5 embryo (Samokhvalov et al., 2007) and subsequently in the AGM-region and the placenta (Godin et al., 1995; Medvinsky and Dzierzak, 1996; Rhodes et al., 2008) . In addition, a recent study by Zovein and colleagues demonstrated that definitive hematopoietic progenitors arising in the AGM-region and possibly also in the placenta originate from an endothelial precursor population (Zovein et al., 2008) . Using time-restricted in vivo labelling, we found in the present study that SCL-tagged cells arising during gastrulation completely failed to give rise to adult blood ( Fig. 5 and S7, E7.75). However, when marking was extended until E8.75 and further, we were able to target a second population of cells capable of reaching adulthood (Fig. 5 and S7 ). The fact that E8.75 genetically SCL-marked cells have progeny which can be detected postnatally as late as one year (data not shown) strongly suggests that these progenitors are multilineage hematopoietic stem cells. By contrast, no contribution of SCL-labelled cells arising during gastrulation was observed in aged mice. The lack of multilineage and delayed hematopoietic potential within the initially SCL-labelled progenitor population is in contrast to the finding that Runx1-tagged yolk sac progenitors give rise to adult blood cell formation (Samokhvalov et al., 2007) . This different spatio-temporal in vivo labelling pattern is most likely to be explained by the use of dissimilar transcriptional elements (SCL and Runx1) and tagging systems (tetO-Cre/RAGE and MER-Cre-MER/ROSA26-YFP). In addition, SCL-mediated marking activity of definitive progenitors was less efficient than tagging of primitive blood cells. Therefore the amount of DOX needed for saturating free tTA-2S molecules and thus for extinguishing genetic marking of definitive blood cell progenitors might have been lower than for primitive blood cells. For this reason we cannot completely rule out the possibility that SCL-marked definitive progenitors might have emerged prior to E 8.75. However, since DOX application of 42 h was sufficient for preventing marking of primitive blood cells, it is safe to conclude that definitive SCL-marked progenitors were present at E 8.75.
One intriguing result of our in vivo lineage experiments is the fact that only a fraction of definitive blood cells underwent Cre-recombination even when the system was continuously activated (Fig. 5, ÀDOX) . By contrast, when the same SCL-tTA-2S effector mouse was used in combination with the tetO-H2B-GFP system, 80% of hematopoietic stem cells were labelled (Wilson et al., 2008) . This discrepancy is most likely due to the use of distinct DOX-responsive elements (tetO-Cre/RAGE-EGFP or tetO-H2B-GFP), which might differently respond to the SCL-tTA-2S stimulus. Although the number of recombined adult blood cells derived from E8.75 tagged cells was low, it was sufficient to determine the adult fate of these progenitors by flow cytometry. As evidenced by these experiments, E8.75 SCL-tagged cells contributed to erythroid, myeloid and lymphoid lineages and to lin À /c-kit + HSCs and progenitors (Fig. 6D ). Since the initial wave of SCL-tagged cells did not contribute to adult hematopoiesis and since labelling of definitive hematopoietic precursors took place at the same time when the first SCL-marked cells emerge in the dorsal aorta (Fig. 2C) , it is tempting to speculate that the second wave of SCL-marking targeted AGM-derived hematopoietic progenitors. However, in our experiments definitive progenitors were first labelled at a developmental time point when embryonic circulation is already initiated, and therefore the precise anatomical origin of these cells remains to be determined. Using continuous SCL-marking, we did not identify any contribution of SCL-tagged cells to the vasculature of the developing embryo (Fig. 4, S5 and data not shown). Given that low level SCL activity is detectable in endothelial tissues of the early embryo (Drake et al., 1997; Drake and Fleming, 2000; Kallianpur et al., 1994) , it is evident that the expression levels of the tTA-2S effector did not reach the threshold required to switch on the downstream tetO-Cre and R26R lacZ allele in endothelial cells. Since all descendants of SCL-tagged ancestor cells preserve a genetically activated reporter gene, it is safe to conclude that SCL-tagged cells did not have any potential to contribute to the endothelial compartment and thus represent a population which is already committed to the hematopoietic fate. Developmental restriction of embryonic progenitor cells to the hematopoietic fate as seen in our experiments and also previously reported by other researchers (Samokhvalov et al., 2007; Stadtfeld and Graf, 2005) together with the recent finding that AGM and possibly also placenta derived endothelial cells have multilineage hematopoietic potential (Zovein et al., 2008) strongly suggest a polyclonal origin of progenitor cells, able to contribute to definitive hematopoiesis.
In summary, our data provide direct in vivo evidence for the establishment of primitive hematopoiesis in the mid to late streak embryo and demonstrate that a population of multilineage hematopoietic progenitors contributing to erythroid, myeloid and lymphoid development is present at E8.75. Our results emphasize the importance of studying developmental pathways in their native environment and underscore the experimental potential of this novel approach. The ability to specifically mark blood progenitors and to identify discrete hematopoietic pathways in vivo will now provide the opportunity to explore further the regulatory mechanisms and developmental niches required for hematopoietic specification and lineage establishment.
4.
Experimental procedures
Animals
The SCL-tTA-2S knock-in mouse (Bockamp et al., 2006) , the tetO-Cre responder mouse line (Saam and Gordon, 1999) , the R26R flox-STOP-flox lacZ (Soriano, 1999) and RAGE-EGFP (Constien et al., 2001 ) Cre-reporter lines have been previously described.
4.2.
In vivo lineage tracing using timed mated mice
To ensure accurately-timed mating periods SCL-tTA-2S male mice were mated with bi-transgenic tetO-Cre/RAGE-EGFP or tetO-Cre/R26R lacZ female mice for 2 h in the morning. The marking process was terminated by administering the mice a solution of 3 mg DOX (Sigma)/ml water containing 1% sucrose. To ensure the immediate uptake of DOX, pregnant dams were deprived of liquid for 1 day prior to administering the DOX-containing drinking water.
4.3.
X-gal staining and intra-embryonic visualization of lacZ + cells Wholemount X-gal staining was performed as described (Bockamp et al., 2006) . To be able to detect lacZ + cells localized within the embryo, X-gal stained wholemount animals were dehydrated using graded steps into 100% methanol and subsequently transferred into equal parts of benzyl benzoate:benzyl alcohol (1:1).
FACS analysis
Lineage contribution of EGFP-marked blood cells was analyzed with a FACSCalibur (Becton Dickinson, BD) by co-staining with PE-conjugated antibodies against CD11b, CD19, Gr1, Ter119, CD71 (BD), CD3, CD11c, DX5 (Caltag), CD23 (Southern) or with purified antibodies against CD41 (BD) detected with anti-rat-PE (Caltag). The stem cell fraction was defined by lin-PE À and c-kit-APC + (BD Biosciences) staining. For determining Ter119 and CD71 expression of EGFP-marked primitive blood cells, pooled E8.5 yolk sacs (n = 30) or E9 conceptuses (n = 20) were suspended in PBS (phosphate buffered saline pH 7.4) containing 5% foetal calf serum using repeated pipetting. Prior to staining with the first antibody, cells were blocked with PBS containing 20% rat serum. Specific staining was confirmed using appropriate isotype controls.
Confocal microscopy and immunostaining
Wholemount staining with rat monoclonal anti-CD31 antibody (MEC13.3 provided by Elisabetta Dejana) has been previously described (Liebner et al., 2004) . Briefly, embryos were fixed with 2% (w/v) paraformaldehyde in PBS, permeabilized with 0.02% (v/v) NP-40 in PBS, and stained for b-gal activity. For subsequent immunofluorescent staining whole embryos were blocked with 1% (v/v) BSA, 0.5% TritonX-100 in PBS overnight at 4°C. Incubation with primary antibodies was carried out overnight at 4°C. After washing in PBS fluorescently labelled streptavidin was added for 2 h at room temperature. After additional washing in PBS, specimens were mounted using PolyMount (Polysciences Europe) and digitally documented using a spectral imaging confocal microscope (C1si, Nikon). The non-fluorescent blue lacZ staining was documented in reflection mode using a 488 nm laser. Images were processed using the NIH ImageJ software and Adobe Photoshop CS. Optical sections through the E8 conceptus were obtained with a Leica TCS SP2 confocal microscope, using Leica LSC image acquisition software. Movies were produced with Marcomedia Director.
